Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma

Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the a...

Full description

Saved in:
Bibliographic Details
Published inInternational reviews of immunology Vol. 38; no. 2; pp. 79 - 91
Main Authors Eskian, Mahsa, Khorasanizadeh, MirHojjat, Zinzani, Pier Luigi, Illidge, Tim M., Rezaei, Nima
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 04.03.2019
Subjects
Animals
Chelating Agents - chemistry
Chelating Agents - pharmacology
Disease Management
Drug Compounding
Drug Synergism
Enhancing efficiency
Humans
Isotope Labeling
Ligands
Lymphoma, Non-Hodgkin - etiology
Lymphoma, Non-Hodgkin - therapy
non-Hodgkin lymphoma
novel method
Oligodeoxyribonucleotides - chemistry
Oligodeoxyribonucleotides - pharmacology
Polyethylene Glycols - chemistry
pretargeting
promoting
Radiation-Sensitizing Agents - chemistry
Radiation-Sensitizing Agents - pharmacology
radioimmunotherapy
Radioimmunotherapy - methods
Treatment Outcome
novel method
promoting
Enhancing efficiency
non-Hodgkin lymphoma
pretargeting
radioimmunotherapy
Online AccessGet full text

Cover

More Information
Summary:Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the aggressive or relapsed/refractory NHL subjects experience relapses following RIT. Although more aggressive treatments such as myeloablative doses of RIT followed by stem cell transplantation appear to be able to provide a longer survival for some patients these approaches are associated with significant treatment-related adverse events and challenging to deliver in most centers. Therefore, it seems reasonable to develop treatment approaches that enhance the efficiency of RIT, while reducing its toxicity. In this paper, novel methods that improve the efficiency of RIT and reduce its toxicity through various mechanisms are reviewed. Further clinical development of these methods could expand the NHL patient groups eligible for receiving RIT, and even extend the use of RIT to new indications and disease groups in future.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0883-0185
1563-5244
1563-5244
DOI:10.1080/08830185.2019.1588266